Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.
Gregory L HundemerRobert TalaricoNavdeep TangriSilvia J LeonSarah E BotaEmily RhodesGreg A KnollManish M SoodPublished in: Clinical journal of the American Society of Nephrology : CJASN (2021)
Among older adults with RAASi-related hyperkalemia, RAASi discontinuation is associated with the lowest risk of recurrent hyperkalemia, with no apparent increase in short-term risks for cardiovascular events or all-cause mortality.